


Is joint hypermobility linked to self-reported non-recovery from COVID-19? Case-control evidence from the British COVID Symptom Study Biobank

Jessica A Eccles,^{1,2} Dorina Cadar,¹ Lisa Quadt ,^{1,2} Alan J Hakim,^{3,4} Nicholas Gall,⁵ Covid Symptom Survey Biobank Consortium,⁶ Vicky Bowyer,⁶ Nathan Cheetham,⁶ Claire J Steves,^{6,7} Hugo D Critchley,^{1,2} Kevin A Davies⁸

To cite: Eccles JA, Cadar D, Quadt L, *et al*. Is joint hypermobility linked to self-reported non-recovery from COVID-19? Case-control evidence from the British COVID Symptom Study Biobank. *BMJ Public Health* 2024;**2**:e000478. doi:10.1136/bmjph-2023-000478

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjph-2023-000478>).

Received 8 August 2023
Accepted 7 December 2023



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Dr Jessica A Eccles;
j.eccles@bsms.ac.uk

ABSTRACT

Objectives This study sought to explore whether generalised joint hypermobility (GJH, a common marker of variant connective tissue) was a risk factor for self-reported non-recovery from COVID-19 infection.

Design Prospective observational study.

Setting COVID Symptom Study Biobank (<https://cssbiobank.com/>) UK

Participants Participants were surveyed in August 2022. 3064 (81.4%) reported at least one infection with COVID-19. These individuals self-reported on recovery and completed a self-report questionnaire to detect GJH (Hakim and Grahame 5-part questionnaire, 5PQ).

Main outcome measures The primary outcome was the presence of self-reported non-recovery from COVID-19 infection at the time of the survey. Additional outcomes included scores on 5PQ and self-reported fatigue level (Chalder Fatigue Scale).

Results The presence of GJH was not specifically associated with reported COVID-19 infection risk per se. However, it was significantly associated with non-recovery from COVID-19 (OR 1.43 (95% CI 1.20 to 1.70)). This association remained after sequential models adjusting for age, sex, ethnic group, education level and index of multiple deprivation (OR 1.33 (95% CI 1.10 to 1.61)) and further adjustment for vaccination status and number of vaccinations (OR 1.33 (95% CI 1.10 to 1.60)). Additionally, including in a model adjusting for all covariates, hypermobility significantly predicted higher fatigue levels (B=0.95, SE=0.25, t=3.77, SE, p=0.002). Fatigue levels mediated the link between GJH and non-recovery from COVID-19 (estimate of indirect effect=0.18, 95% bootstrapped CI 0.08 to 0.29).

Conclusions Individuals with GJH were approximately 30% more likely not to have recovered fully from COVID-19 infection at the time of the questionnaire, and this predicted the fatigue level. This observation is clinically important through its potential impact for understanding and identifying sub-phenotypes of long COVID for screening and personalised targeted interventions. More generally, greater awareness of GJH and its extra-articular associations is needed for effective patient stratification and implementation of personalised medicine.

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Long COVID represents one of the greatest clinical challenges and public health burdens of a generation.
- ⇒ In addition to demographic factors such as increased age, the likelihood of developing long COVID appears to be increased by the presence of a pre-existing activity-limiting health condition or disability; for example, fibromyalgia, irritable bowel syndrome, migraine, allergies, anxiety, depression and back pain are among a number of conditions identified as raising the risk of long COVID. These risk factors have all independently been associated with a common variant of connective tissue—namely, joint hypermobility.
- ⇒ Currently no studies have explicitly explored the potential unifying link of generalised joint hypermobility as a risk factor for not recovering fully from COVID-19 infection.

WHAT THIS STUDY ADDS

- ⇒ This study suggests that the presence of generalised joint hypermobility may be a risk factor for not recovering fully from COVID-19 and predicts greater fatigue levels.
- ⇒ This has significant implications for further research, clinical practice and public health, including precision healthcare approaches.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ This study highlights the need for research on predisposing factors and comorbidities on risk factors, particularly as they relate to variant connective tissue (joint hypermobility)
- ⇒ The study also highlights the need for stratified personalised healthcare for patients and the need to inform and plan policy and multidisciplinary service provision for those with long COVID and related conditions.

INTRODUCTION

What is the clinical problem?

The COVID-19 pandemic and the burden of subsequent limited recovery from COVID-19¹

present some of the greatest clinical challenges of a generation. Such individuals not fully recovered from COVID-19 may self-identify under the collective patient-advocated term ‘long COVID’ and/or meet one of the various clinical definitions created to describe persistent symptoms.² National data from March 2023 indicate that around 3% of the UK population had not recovered fully from COVID-19 infection. The most common associated symptoms are fatigue (72%), difficulty concentrating (51%), muscle aches/pain (49%) and shortness of breath (48%).³ However, more than 200 symptoms, expressed across multiple organ systems, are associated with delayed recovery following acute COVID-19 infection.¹ A history of infection with COVID-19 is now commonplace,⁴ so a precise and mechanistic understanding of factors that predispose to enduring symptoms and limit recovery will help design and deliver effective healthcare to improve the quality of life of millions of affected individuals worldwide. Evidently, the presentation of long COVID is heterogeneous.⁵ These distinct profiles need further characterisation in order to design personalised care and to target effective treatment across populations and age groups.

What do we know about long COVID at this point?

In addition to demographic factors, notably female sex, the likelihood of developing long COVID appears to be increased by the presence of pre-existing activity-limiting health conditions or disabilities.³ Fibromyalgia, irritable bowel syndrome, migraine, anxiety, depression and back pain⁶ are among a number of conditions identified as raising the risk of long COVID. However, other studies on long COVID have failed to find specific associations, particularly in relation to pre-existing affective disorders.⁷ There is growing awareness of the symptomatic overlap with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), in which viral infection is often implicated as a trigger. Indeed, such research may help elucidate the aetiology of long COVID.⁸ Moreover, cardiovascular autonomic dysfunction, particularly postural orthostatic tachycardia syndrome (POTS), may be precipitated by COVID-19 and expressed in long COVID.⁹ POTS is a chronic and often disabling disorder characterised by orthostatic intolerance with an excessive increase in heart rate without hypotension during upright posture. Patients often experience a constellation of other typical symptoms overlapping with long COVID including fatigue and exercise intolerance, and it is established that the onset of POTS may be precipitated by immunological stressors. A variety of pathophysiologies are involved in the abnormal postural tachycardia response; however, the precise aetiology of the syndrome is incompletely understood and is undoubtedly multifaceted.¹⁰ Indeed, the presence of POTS is considered to be a major sub-phenotype of long COVID, with an estimated prevalence of 30–75% in symptomatic patients, depending on methodology.^{11–13} These conditions (POTS, ME/CFS) are archetypes of seemingly complex poorly-understood

multisystem illnesses, alongside hypermobility spectrum disorder (HSD)¹⁴ and Ehlers–Danlos syndrome, which we discuss further below.¹⁵ The mechanisms and pathobiology behind the association of long COVID with these multiple co-occurring conditions are currently poorly understood. However, convergent biological mechanisms, including dysregulated autonomic, inflammatory and metabolic processes, are increasingly implicated in the expression and maintenance of long COVID.^{1 16 17} Understanding and managing such complexity can be challenging to clinicians who may resort to heuristic classifications such as ‘functional’ disorder. As a consequence, many patients report stigmatisation and can wait years for a diagnosis to access appropriately targeted and potentially effective treatment.¹⁸ Similar perceptions appear to be emerging in relation to long COVID.^{19 20} This may compromise the planning and delivery of cost-effective and timely therapy, both at the level of the individual patients and the level of healthcare service provision.

There is growing interest in how variant connective tissue (often recognised by the presence of generalised joint hypermobility (GJH)) may represent a common constitutional factor predisposing to such complex multi-system conditions and disorders (see [box 1](#)). GJH is a characteristic marker of hereditary disorders of connective tissue, which ultimately compromises a matrix of proteins that includes collagens, elastins, fibrillins and tenascins. Joint hypermobility is typically more common in females and declines with age. GJH itself is not necessarily a medical problem, but certain clinical phenotypes, notably hypermobile Ehlers–Danlos syndrome (hEDS; previously known as EDS hypermobility type/EDS type-III) and hypermobility spectrum disorder (HSD) are associated with clinically significant issues, including chronic disabling fatigue and dysautonomia.¹⁴ Around 20% of the UK population fulfil the criteria for GJH as an indicator of variant connective tissue structure.²¹ However, less clear is whether individuals with GJH are predisposed to COVID-19 infection and impaired recovery.

Aim of this study

The aim of this study was to determine, from the UK COVID Symptom Study Biobank (CSSB), if the presence of GJH is associated with an increased risk of not recovering fully from infection with COVID-19.

METHODS

Public and patient involvement

The research question, choice of hypermobility measures and dissemination strategy was informed by patient and public involvement including priorities, experience and preferences of those living with long COVID. This was crystallised at a POTS UK Long COVID masterclass in 2022 and has been supported by ongoing involvement.

Box 1 Clinical phenomena associated with symptomatic joint hypermobility (HSD/EDS)

Strong association with symptomatic joint hypermobility (HSD/EDS):

- ⇒ Chronic pain (including headache, migraine and orofacial pain due to temporomandibular joint disease; visceral pain; musculoskeletal pain including oligoarticular/polyarticular pain, and neuropathic pain).
- ⇒ Chronic fatigue sufficiently disabling to interfere with day-to-day function.
- ⇒ Functional gastrointestinal disorders (Rome IV criteria), including slow gastrointestinal transit.
- ⇒ Postural orthostatic tachycardia syndrome, orthostatic hypotension, orthostatic intolerance.
- ⇒ Neurological manifestations (in adults): atlanto-axial/cranio-cervical joint instability, Chiari 1 malformation, small fibre neuropathy/disease, local anaesthetic resistance.
- ⇒ Developmental coordination disorder.
- ⇒ Anxiety disorders, phobias, depression.

Evolving evidence of clinical association with symptomatic joint hypermobility (HSD/EDS), however this remains an area with clinical and scientific uncertainties:

- ⇒ Neurally-mediated hypotension.
- ⇒ Neurological manifestations (in children and adolescents).
- ⇒ Interstitial cystitis.
- ⇒ Underactive and hyperactive bladder.
- ⇒ Dysmenorrhoea or dysmenorrhagia.
- ⇒ Attention deficit/hyperactivity disorder and autism.
- ⇒ Immune dysregulation, intolerances and allergies.

Adapted and reproduced with permission of the hEDS/HSD Working Group, The International Consortium on the Ehlers-Danlos syndromes and Hypermobility Spectrum Disorders.

The CSSB is supported by patient and public involvement in order to determine opinions and perspectives of those affected by COVID during the development and running of their research. To help with this, the CSSB has Volunteer Advisory Panels (VAPs). VAPs each consist of 12 representative participants from across the UK. The panels were formed in summer 2021 and member terms are 2 years. Examples of how VAP members advise CSSB research include giving feedback about the feasibility of research plans and suggesting perspectives for researchers to consider when planning investigations and considering results.

Participants

Data were extracted from the UK CSSB, which was linked to demographic data, SARS-CoV-2 test results and symptom assessment data from the COVID Symptom Study app, a mobile health application developed by ZOE Global with input from physicians and scientists at King's College London, Massachusetts General Hospital, and Lund and Uppsala Universities.^{22 23}

Outcomes

GJH was determined using the 5-part Hakim and Grahame self-report questionnaire (5PQ), where a score

Box 2 The 5-part Hakim and Grahame Questionnaire (5PQ) for defining generalised joint hypermobility

1. Can you now (or could you ever) place your hands flat on the floor without bending your knees?
 2. Can you now (or could you ever) bend your thumb to touch your forearm?
 3. As a child did you amuse your friends by contorting your body into strange shapes OR could you do the splits?
 4. As a child or teenager did your shoulder or kneecap dislocate on more than one occasion?
 5. Do you consider yourself double-jointed?
- Endorsement of two or more questions suggests generalised joint hypermobility.

of ≥ 2 indicates GJH (see [box 2](#) for details).²⁴ Recovery from COVID-19 was operationalised from a dichotomous self-reported response to the question “Thinking about the last or only episode of COVID-19 you have had, have you now recovered and are back to normal?” These questions were surveyed as part of the CSSB in August 2022. Fatigue level was quantified by the Chalder Fatigue Scale.

Statistical analysis

Binary logistic regression was used to determine if the presence of GJH was a predictor of non-recovery from COVID-19. Age, sex, ethnic group, socioeconomic status (index of multiple deprivation quintile) and education level, vaccination status and number of vaccinations were entered as potential confounders in sequential models. Linear regression was used to explore associations between GJH and fatigue levels, with covariates as above. Mediation analyses were conducted according to the method of Hayes. In such a model a variable is considered to be a likely mediator of the relationship between two independent variables if the bootstrapped CI of the estimate of the indirect effect of the mediator variable on that relationship does not cross zero.²⁵ All data were analysed using IBM SPSS Statistics 28.

RESULTS

In this sample, 3064 (81.4%) reported at least one infection with COVID-19. Of these individuals, data regarding self-reported recovery were available for 2854 participants (2331 (81.7%) female; 2767 (97.4%) white), with a mean age of 57.5 years (range 21–89). A full demographic breakdown is shown in [table 1](#). Reporting at least one COVID-19 infection was not significantly associated with GJH.

Of the 914 participants (32.0%) who reported not having recovered fully from COVID-19 infection, 269 patients (254 (29.4%) female) had GJH. In the fully recovered group, 439 of 1940 patients (22.6%, 400 female) had GJH.

GJH was significantly associated with not having recovered from COVID-19 (Model 1; B=0.355, $p < 0.001$) with OR 1.43 (95% CI 1.20 to 1.70). This association

Table 1 Demographics of sample

	Overall	COVID recovered	COVID non-recovered
Number (%)	2854	1940 (67.8%)	914 (32%)
Female, n (%)	2331 (81.7%)	1556 (80.2%)	775 (84.8%)
White, n (%)	2767 (97.0%)	1889 (97.4%)	878 (96.1%)
Age, mean (SD)	57.50 (10.45)	57.95 (10.48)	56.54 (10.31)
Generalised joint hypermobility, n (%)	708 (24.8%)	439 (22.6%)	269 (29.4%)

remained significant after sequential corrections for age and sex (Model 2), ethnic group, socioeconomic status and education level (Model 3) (see online supplemental table 1 for details).

In the final model (Model 4, online supplemental table 2) also adjusting for vaccination status and number, GJH remained significantly associated with not having recovered from COVID (B=0.282, p=0.003) with OR 1.33 (95% CI 1.10 to 1.60).

Furthermore, in a model adjusting for all covariates, GJH significantly predicted higher fatigue levels (B=0.95, SE=0.25, t=3.77, SE, p=0.002). Moreover, fatigue levels mediated the link between GJH and non-recovery from

COVID-19 (estimate of indirect effect=0.18, bootstrapped 95% CI do not cross zero, 0.08 to 0.29) (see figure 1 for details of mediation model).

DISCUSSION

In this large population-based study, an individual with GJH (an index of variant connective tissue structure) was approximately 30% more likely not to have recovered after initial COVID-19 infection. This observation is clinically important through its potential impact for understanding and identifying sub-phenotypes of long COVID for screening and personalised targeted interventions.




Figure 1 Mediation model showing likely mediating link of fatigue in the relationship between generalised joint hypermobility and not recovering from COVID-19.

To our knowledge, this is the first published study to directly report on the association between recovery from COVID-19 and a common variant of connective tissue (identifiable from GJH). Furthermore, we propose that this linked through the fatigue level, suggesting that GJH may represent a subtype of those with persistent symptoms from COVID-19. Our study was conducted in a relatively large sample and included comparison with those who had recovered from COVID-19 infection. Our findings are in common with a recent survey exploring GJH in long COVID alone, which found an increased risk of joint, muscle/nerve pain and cognitive fatigue symptoms.²⁶

GJH is frequently under-reported and clinically significant subtypes are underdiagnosed. However, this manifestation of a variant of connective tissue is a significant but maybe a commonly overlooked contributing factor to medical consultations.²⁷ It is likely a constitutional feature predisposing to a number of multisystem features. In a recent study of patients with clinically significant pain and fatigue (fibromyalgia and ME/CFS) we observed that the majority (81%) also had symptomatic joint hypermobility, yet less than a quarter of these individuals had received a previous diagnosis.²⁸

A major strength of the present study is our use of a widely used and well-validated screening tool to detect GJH in those who are likely unaware of their own joint hypermobility status. The conventional way to identify GJH is by a physical examination, scored according to the Beighton score.²⁹ This is both a strength and a limitation; however, Beighton scoring can be time consuming in clinical practice and is often unfeasible in large population-based studies. The 5PQ was developed using the Beighton scale as a reference standard, with high sensitivity and specificity of 71–84% and 77–89%, respectively.³⁰

A limitation of this study is our inclusion of a predominantly female and white sample. Also, the lack of a stringent fixed definition of long COVID (beyond not recovering in full from COVID-19 infection) represents a potential general weakness, but it aligns with the ecological and pragmatic approach taken by the UK Office of National Statistics. Furthermore, the present analysis does not include or correct for possible confounders such as duration of symptoms and coronavirus variant type, or pre-existing conditions such as fibromyalgia, a condition in which nocioplastic pain and associated symptoms such as fatigue and brain fog are characteristic. A similar issue has recently been raised in the context of patients with pre-existing inflammatory conditions in which similar difficulties arise when interpreting the individual contribution of COVID-related morbidity in the context of pre-existing symptomatology related to underlying inflammatory rheumatic disease.³¹

Our finding that not recovering fully from COVID-19, alongside female sex, is associated with a constitutional feature (GJH) predisposing to premorbid health conditions is consistent with other larger studies and meta-analyses.^{1 32} An examination of over one million

individual electronic healthcare records in the UK concluded that delayed recovery from COVID-19 was associated with poor pre-pandemic general and mental health.³³ A recent review of what is understood about long COVID highlighted potential developmental and immune risk factors including attention deficit hyperactivity disorder, chronic urticaria and allergic rhinitis. This review also noted the potential mechanistic and phenotypic overlap with illnesses including ME/CFS.¹ An analysis of risk factors for long COVID, in which 384 137 individuals were followed up for a minimum of 3 months following acute COVID-19 infection, found the strongest associations with long COVID included fibromyalgia (adjusted Hazard Ratio (aHR) 1.37, 95% CI 1.28 to 1.47), anxiety (aHR 1.35, 95% CI 1.31 to 1.39), depression (aHR 1.31, 95% CI 1.27 to 1.34), migraine (aHR 1.26, 95% CI 1.22 to 1.30), multiple sclerosis (aHR 1.26, 95% CI 1.03 to 1.53), coeliac disease (aHR 1.25, 95% CI 1.09 to 1.43) and learning disability (aHR 1.24, 95% CI 1.11 to 1.40).⁶ GJH, although advantageous in some contexts, is an index of variant connective tissues throughout bodily systems and is consequently associated with a number of co-occurring physical and psychological health conditions³⁴ (see [box 1](#)); joint hypermobility is increasingly implicated as a unifying trait that may underlie all of the conditions noted above.^{28 35–41} Moreover, it is highly associated⁴² with POTS, a manifestation of dysautonomia and one of the most frequently identified sequelae of long COVID.¹¹

As previously suggested, long COVID is likely a heterogeneous entity encompassing and intersecting immunological, inflammatory, autonomic, respiratory and cardiovascular processes that lead to distinct profiles of symptoms affecting body and brain.⁵ There are probably multifactorial aetiologies and therefore no single treatment strategy for long COVID. However, these results suggest further exploration of whether GJH is linked to a particular phenotype or subtype of those not recovering fully from COVID-19, including long COVID.

GJH may be regarded by many clinicians as an incidental finding or simple variation of normality, where hyperextensible joints may almost represent a clinical ‘red herring’. However, the presence of joint laxity provides an important clue to differences in connective tissue composition that can affect multiple bodily systems. Our findings suggest an increased risk of not recovering fully from COVID-19 for those with joint hypermobility. If this is ultimately associated with a distinct phenotype, this will facilitate screening and personalised treatments—for example, targeting autonomic dysfunction.

This study offers fresh and novel insights into understanding the potential links between pre-existing conditions and long COVID. Confirming these findings in larger and more diverse samples will permit detailed characterisation of those features of GJH (and variant connectivity tissue) that predict particular long COVID phenotypes, with mechanistic implications. Any such study should focus on the contribution of pre-existing

conditions as potential risk factors, particularly those associated with multiple bodily symptoms including nocioplastic pain and autonomic dysfunction. More generally, greater awareness of joint hypermobility and of its extra-articular associations is needed for effective patient stratification and implementation of personalised medicine at the level of the individual and society.

Author affiliations

¹Department of Clinical Neuroscience, Brighton and Sussex Medical School, Brighton, UK

²Neurodevelopmental Service, Sussex Partnership NHS Foundation Trust, Worthing, UK

³Division of Medicine, School of Medicine, Penn State University, University Park, Pennsylvania, USA

⁴Department of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK

⁵Department of Neurocardiology, King's College Hospital NHS Foundation Trust, London, UK

⁶Department of Twin Research and Genetic Epidemiology, King's College London, London, UK

⁷Department of Ageing and Health, Guys and St Thomas's NHS Foundation Trust, London, UK

⁸Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK

Twitter Jessica A Eccles @bendybrain and Lisa Quadt @LisaQuadt

Acknowledgements The authors would like to acknowledge the contributions of Philip Bull, Regina Torok and Jeffrey Lubell and those with lived experience of long COVID. We thank the CSSB team and Volunteer Advisory Panel.

Collaborators We would like to acknowledge the contribution of the individual Covid Symptom Biobank Consortium members: Michela Antonelli, Vicky Bowyer, Julia Brown, Joan Capdevila Pujol, Nathan Cheetham, Lynn Cherkas, Jie Deng, Katie Doores, Emma Duncan, Maria Garcia, Alexander Hammers, Deborah Hart, Nicholas Harvey, Adrian Hopper, Christina Hu, Eric Kerfoot, Michael Malim, Marc Modat, Erika Molteni, Benjamin Murray, Ayrin Nessa, Sebastien Ourselin, Tim Spector, Claire Steves, Carole Sudre, Samuel Wadge, and Jonathan Wold.

Contributors The guarantor (JE) accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. JE, HDC, LQ, KAD and CJS formulated the research question alongside patient and public involvement, including that led by NG and AJH. AJH designed the 5PQ. The data acquisition was overseen at CCSB by CJS, NC and VB. The CSSB was supported by the CSSB Consortium. The analysis and interpretation was conducted by JE and DC. JE drafted the work and all authors revised it critically for important intellectual content and gave final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. JE acts as guarantor.

Funding The CSS Biobank is supported by the Chronic Disease Research Foundation. NC is supported by NIHR via their institution; CJS is supported by UKRI, Wellcome Trust and Chronic Disease Research Foundation via their institution. JE is supported by a MQ/Versus Arthritis Fellowship (MQF 17/19)

Competing interests CJS declares a consultancy contract with ZOE Ltd.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research (see Methods section for further details).

Patient consent for publication Not applicable.

Ethics approval Ethical approval for the ZOE app was from King's College London Research Ethics Office (LRS-19/20-18210) and for the CSSB from Yorkshire & The Humber - Leeds East Research Ethics Committee (20/YH/0298). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request from the UK COVID Symptom Study Biobank (CCSB) and are not publicly available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iD

Lisa Quadt <http://orcid.org/0000-0002-5896-916X>

REFERENCES

- Davis HE, McCorkell L, Vogel JM, *et al*. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023;21:133–46.
- Munblit D, O'Hara ME, Akrami A, *et al*. Long COVID: aiming for a consensus. *Lancet Respir Med* 2022;10:632–4.
- Office for National Statistics (ONS). Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. 2023. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023>
- Office for National Statistics (ONS). Coronavirus (COVID-19) infection survey technical article: cumulative incidence of the percentage of people who have been infected with COVID-19 by variant and age, England: 9 February 2023. 2023. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveytechnicalarticlecumulativeincidenceofthenumberofpeoplewhohavebeeninfectedwithcovid19byvariantandageengland/9february2023>
- Canas LS, Molteni E, Deng J, *et al*. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations. *Lancet Digit Health* 2023;5:e421–34.
- Subramanian A, Nirantharakumar K, Hughes S, *et al*. Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat Med* 2022;28:1706–14.
- Lamontagne SJ, Winters MF, Pizzagalli DA, *et al*. Post-acute sequelae of COVID-19: evidence of mood and cognitive impairment. *Brain Behav Immun Health* 2021;17:100347.
- Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. *Trends Mol Med* 2021;27:895–906.
- Mallick D, Goyal L, Chourasia P, *et al*. COVID-19 induced postural orthostatic tachycardia syndrome (POTS): a review. *Cureus* 2023;15:e36955.
- Vernino S, Bourne KM, Stiles LE, *et al*. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. *Auton Neurosci* 2021;235:S1566-0702(21)00058-8.
- Fedorowski A, Sutton R. Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome. *Nat Rev Cardiol* 2023;20:281–2.
- Seeley M-C, Gallagher C, Ong E, *et al*. High incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long COVID: implications for management and health care planning. *Am J Med* 2023;S0002-9343(23)00402-3.
- Larsen NW, Stiles LE, Shaik R, *et al*. Characterization of autonomic symptom burden in long COVID: a global survey of 2,314 adults. *Front Neurol* 2022;13:1012668.
- Castori M, Tinkle B, Levy H, *et al*. A framework for the classification of joint hypermobility and related conditions. *Am J Med Genet C Semin Med Genet* 2017;175:148–57.

- 15 Tinkle B, Castori M, Berglund B, *et al.* Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history. *Am J Med Genet C Semin Med Genet* 2017;175:48–69.
- 16 Eccles JA, Davies KA. The challenges of chronic pain and fatigue. *Clin Med* 2021;21:19–27.
- 17 Missailidis D, Annesley SJ, Fisher PR. Pathological mechanisms underlying myalgic encephalomyelitis/chronic fatigue syndrome. *Diagnostics* 2019;9:80.
- 18 Halverson CME, Penwell HL, Francomano CA. Clinician-associated traumatization from difficult medical encounters: results from a qualitative interview study on the Ehlers-Danlos syndromes. *SSM Qual Res Health* 2023;3:100237.
- 19 Walker AJ, MacKenna B, Inglesby P, *et al.* Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. *Br J Gen Pract* 2021;71:e806–14.
- 20 Baz SA, Fang C, Carpentieri JD, *et al.* 'I don't know what to do or where to go'. Experiences of accessing healthcare support from the perspectives of people living with long Covid and healthcare professionals: a qualitative study in Bradford, UK. *Health Expect* 2023;26:542–54.
- 21 Mulvey MR, Macfarlane GJ, Beasley M, *et al.* Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale general population-based survey. *Arthritis Care Res (Hoboken)* 2013;65:1325–33.
- 22 Menni C, Valdes AM, Freidin MB, *et al.* Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med* 2020;26:1037–40.
- 23 Drew DA, Nguyen LH, Steves CJ, *et al.* Rapid implementation of mobile technology for real-time epidemiology of COVID-19. *Science* 2020;368:1362–7.
- 24 Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility: an adjunct to the assessment of patients with diffuse musculoskeletal pain. *Int J Clin Pract* 2003;57:163–6.
- 25 Hayes AF. *Introduction to mediation, moderation, and conditional process analysis: a regression-based approach*, 2nd edn. Guilford Publications, 2017.
- 26 Hypermobility Syndromes Association. Long Covid - new research and early findings. 2023. Available: <https://www.hypermobility.org/post/long-covid-new-research>
- 27 Grahame R. Hypermobility: an important but often neglected area within rheumatology. *Nat Clin Pract Rheumatol* 2008;4:522–4.
- 28 Eccles JA, Thompson B, Themelis K, *et al.* Beyond bones: the relevance of variants of connective tissue (hypermobility) to fibromyalgia, ME/CFS and controversies surrounding diagnostic classification: an observational study. *Clin Med (Lond)* 2021;21:53–8.
- 29 Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. *Ann Rheum Dis* 1973;32:413–8.
- 30 Hakim AJ, Cherkas LF, Grahame R, *et al.* The genetic epidemiology of joint hypermobility: a population study of female twins. *Arthritis Rheum* 2004;50:2640–4.
- 31 Boekel L, Atiqi S, Leeuw M, *et al.* Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands. *Lancet Rheumatol* 2023;5:e375–85.
- 32 Notarte KI, de Oliveira MHS, Peligro PJ, *et al.* Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-analysis. *J Clin Med* 2022;11:7314.
- 33 Thompson EJ, Williams DM, Walker AJ, *et al.* Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. *Nat Commun* 2022;13:3528.
- 34 Hakim AJ, Tinkle BT, Francomano CA. Ehlers-Danlos syndromes, hypermobility spectrum disorders, and associated co-morbidities: reports from EDS ECHO. *Am J Med Genet C Semin Med Genet* 2021;187:413–5.
- 35 Alsiri N, Alhadhoud M, Alkatefi T, *et al.* The concomitant diagnosis of fibromyalgia and connective tissue disorders: a systematic review. *Semin Arthritis Rheum* 2023;58:S0049-0172(22)00178-0.
- 36 Sharp HEC, Critchley HD, Eccles JA. Connecting brain and body: transdiagnostic relevance of connective tissue variants to neuropsychiatric symptom expression. *World J Psychiatry* 2021;11:805–20.
- 37 Henderson FC Sr, Austin C, Benzel E, *et al.* Neurological and spinal manifestations of the Ehlers-Danlos syndromes. *Am J Med Genet C Semin Med Genet* 2017;175:195–211.
- 38 Danese C, Castori M, Celletti C, *et al.* Screening for celiac disease in the joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type. *Am J Med Genet A* 2011;155A:2314–6.
- 39 Csecs JLL, Iodice V, Rae CL, *et al.* Joint hypermobility links neurodivergence to dysautonomia and pain. *Front Psychiatry* 2021;12:786916.
- 40 Bragée B, Michos A, Drum B, *et al.* Signs of intracranial hypertension, hypermobility, and craniocervical obstructions in patients with myalgic encephalomyelitis/chronic fatigue syndrome. *Front Neurol* 2020;11:828.
- 41 Brock I, Prendergast W, Maitland A. Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder. *Am J Med Genet C Semin Med Genet* 2021;187:473–81.
- 42 Hakim A, O'Callaghan C, De Wandele I, *et al.* Cardiovascular autonomic dysfunction in Ehlers-Danlos syndrome-hypermobility type. *Am J Med Genet C Semin Med Genet* 2017;175:168–74.